BioNTech to Report First Quarter 2020 Financial Results and Operational Update on May 12, 2020
BioNTech SE (Nasdaq: BNTX) will announce its first quarter 2020 financial results on May 12, 2020, at 08:00 a.m. EDT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioNTech SE (Nasdaq: BNTX) will announce its first quarter 2020 financial results on May 12, 2020, at 08:00 a.m. EDT. The company will host a conference call and webcast to present these results alongside a corporate update. The presentation materials will be available online, and a replay will be accessible for 30 days post-call. BioNTech focuses on novel immunotherapies for cancer and serious diseases, utilizing advanced drug platforms. The company collaborates with major pharmaceutical partners, enhancing its biopharmaceutical development capabilities.
Positive
- Strong strategic partnerships with major pharma companies including Pfizer and Eli Lilly.
- Focus on innovative therapies in a growing sector of biopharmaceuticals.
Negative
- Lack of specific financial metrics in the upcoming results could lead to uncertainty for investors.
Details
News Market Reaction – BNTX
The recorded move for BNTX in the trading session of this news was +9.22%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MAINZ, Germany, May 05, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) will announce its financial results for the first quarter 2020 on Tuesday, May 12th, 2020. BioNTech will also host a conference call and webcast on the same day at 08:00 a.m. EDT (2:00 p.m. CET) to report its financial results and provide a corporate update on the first quarter 2020.
The slide presentation and audio of the webcast will be available via the following link: https://edge.media-server.com/mmc/p/eb6fxpp7
To participate in the conference call, please dial the following numbers ten minutes prior to the start and provide the Conference ID:
United States international: +1 646 741 3167
United States domestic (toll-free): +1 877 870 9135
Germany: +49 (0) 692 2222 625
Conference ID: 9282359
Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page of the Investor Relations section of the Company’s website at https://biontech.de/. A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company’s website for 30 days following the call.
About BioNTech
Biopharmaceutical New Technologies (BioNTech) is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Eli Lilly and Company, Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Genevant, Fosun Pharma and Pfizer.
For more information, please visit www.BioNTech.de.
BioNTech’s Investor Relations
Sylke Maas, Ph.D.
VP Investor Relations & Business Strategy
Tel: +49 (0)6131 9084 1074
E-mail: Investors@biontech.de
BioNTech’s Media Relations
Jasmina Alatovic
Senior Manager Global External Communications
Tel: +49 (0)6131 9084 1513 or +49 (0)151 1978 1385
E-mail: Media@biontech.de
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.